Biobot transforms wastewater into privacy-first, predictive intelligence. Using proprietary wastewater data and AI, the company turns biological and chemical signals from sewage into early, actionable insights that help public health agencies, vaccine manufacturers, healthcare systems, and researchers spot emerging trends before they appear in clinical reports.

Founded out of an MIT research project and backed by leading venture investors and SBIR awards from the NIH, Biobot is a global pioneer in wastewater epidemiology and monitors dozens of pathogens and high-risk substances across hundreds of communities.

Biobot’s mission is to protect communities by delivering population-level health intelligence while preserving individual privacy. Their platform provides granular, city- and county-level forecasts, surveillance for pathogens (including SARS‑CoV‑2, influenza, RSV, norovirus and more) and monitoring of substances such as fentanyl and stimulants to inform faster, more equitable public health decisions.

Trusted by organizations including the CDC and NIH and recognized by TIME and Fast Company, Biobot combines laboratory science, data engineering, and machine learning to make wastewater a reliable early-warning system for public health and life-science decision-making.